Navigation Links
Researchers uncover novel process for creation of fuel and chemical compounds
Date:8/5/2014

MADISON, Wis. A team of researchers at the University of Wisconsin-Madison has identified the genes and enzymes that create a promising compound the 19 carbon furan-containing fatty acid (19Fu-FA). The compound has a variety of potential uses as a biological alternative for compounds currently derived from fossil fuels.

Researchers from the Great Lakes Bioenergy Research Center (GLBRC), which is headquartered at UW-Madison and funded by the U.S. Department of Energy, discovered the cellular genomes that direct 19Fu-FA's synthesis and published the new findings Aug. 4 in the journal Proceedings of the National Academy of Sciences.

"We've identified previously uncharacterized genes in a bacterium that are also present in the genomes of many other bacteria," says Tim Donohue, GLBRC director and UW-Madison bacteriology professor. "So, we are now in the exciting position to mine these other bacterial genomes to produce large quantities of fatty acids for further testing and eventual use in many industries, including the chemical and fuel industries."

The novel 19Fu-FAs were initially discovered as "unknown" products that accumulated in mutant strains of Rhodobacter sphaeroides, an organism being studied by the GLBRC because of its ability to overproduce hydrophobic, or water-insoluble, compounds. These types of compounds have value to the chemical and fuel industries as biological replacements for plasticizers, solvents, lubricants or fuel additives that are currently derived from fossil fuels. The team also provides additional evidence that these fatty acids are able to scavenge toxic reactive oxygen species, showing that they could be potent antioxidants in both the chemical industry and cells.

Cellular genomes are the genetic blueprints that define a cell's features or characteristics with DNA. Since the first genome sequences became available, researchers have known that many cells encode proteins with unknown functions according to the instructions specified by the cell's DNA. But without known or obvious activity, the products derived from these blueprints remained a mystery.

As time has gone on, however, researchers have realized that significant pieces of these genetic blueprints are directing the production of enzymes proteins that allow cells to build or take apart molecules in order to survive. These enzymes, it turned out, create new and useful compounds for society.

"I see this work as a prime example of the power of genomics," Donohue says. "It is not often that one identifies genes for a new or previously unknown compound in cells. It is an added benefit that each of these compounds has several potential uses as chemicals, fuels or even cellular antioxidants."

A cross-disciplinary, collaborative effort between GLBRC chemists, biochemists and bacteriologists in departments at UW-Madison and Michigan State University yielded the chemical identity of the fatty acid compounds and identified the specific genes that direct their synthesis in bacteria.

"I don't think this discovery would have been possible," says Rachelle Lemke, the paper's lead author and a research specialist in Donohue's lab, "without the analytical and intellectual expertise of the members from this center."


'/>"/>

Contact: Tim Donohue
tdonohue@bact.wisc.edu
608-262-4663
University of Wisconsin-Madison
Source:Eurekalert

Related biology news :

1. Researchers determine why tendons break down with age
2. Veterinary researchers use nanoparticles to target cancer treatment in dogs, cats
3. Researchers to track effects of revolutionary new medicines
4. UMD researchers develop tool to better visualize, analyze human genomic data
5. New method provides researchers with efficient tool for tagging proteins
6. Researchers uncover secrets of internal cell fine-tuning
7. Whitehead Institute researchers create naïve pluripotent human embryonic stem cells
8. UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies
9. York University researchers use bird backpacks to put wood thrushes migration on the map
10. Intestinal parasites are old friends, researchers argue
11. UNH NHAES researchers work to save endangered New England cottontail
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of ... the latest premium product recently added to the range of products distributed by Ampronix. ... ... ... Medical Display- Ampronix News ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology: